Complete Genomics Names Four Winners of Spatial Xcellerator Grant Program
As the exclusive U.S. distributor of STOmics' Stereo-seq technology for spatial transcriptomics, Complete Genomics launched the Spatial Xcellerator Grant Program and spatial certified service providers last year to promote advancements in spatial omics research.
'We designed the Spatial Xcellerator Grant Program to give scientists access to the most advanced spatial transcriptomics tools available,' said Rob Tarbox, vice president of product and marketing at Complete Genomics. 'The creativity and scientific rigor of the winning projects illustrate the enormous potential of spatial omics to unlock new insights in areas like cancer, neurodegeneration and tissue regeneration. We're proud to support work that will not only push the boundaries of spatial biology but also accelerate the impact of these discoveries on human health.'
Winners of the Spatial Xcellerator Grant Program:
'Spatial transcriptomics provides an unprecedented ability to map gene expression directly within intact and damaged spinal cord tissue, revealing how distinct cell populations and molecular pathways interact at and around the injury site,' said John Kramer, associate professor in the Department of Anesthesiology, Pharmacology & Therapeutics at University of British Columbia, who led one of the winning projects. 'By preserving spatial context, this approach enables researchers to pinpoint region-specific responses, uncover hidden cellular heterogeneity and ultimately gain deeper insights into the mechanisms underlying spinal cord injury and repair.'
About Complete Genomics
Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput cost-effective sequencing technology development since its inception in 2005. Our products have powered over 9,400 publications across a wide array of applications. To learn more, visit www.completegenomics.com.
* For Research Use Only. Not for use in diagnostic procedures.
View original content: https://www.prnewswire.com/news-releases/complete-genomics-names-four-winners-of-spatial-xcellerator-grant-program-302427926.html
SOURCE Complete Genomics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Xtalks Announces its Life Science Webinar Calendar for August 2025
Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain and preclinical. TORONTO, Aug. 1, 2025 /PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field! Visit to see our upcoming webinars: CELL AND GENE THERAPYAugust 22 - How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround CLINICAL TRIALSAugust 7 - Improving Clinical Tech Adoption: Site-Centric ApproachesAugust 13 - Accelerating Clinical Research with Master Protocols: Challenges and Benefits to Complex Trial DesignsAugust 14 - Designing Innovative Trials: Navigating Dose Optimization in Oncology CombinationsAugust 15 - AI in Clinical Trials: Early Use Cases and Innovations COMMERCIALIZATION & HEORAugust 19 - 5 Critical Questions to Ask Before Applying AI to Real-World Data DRUG DISCOVERY & DEVELOPMENTAugust 7 - Oral Dosage Innovation for Pediatric Drug DeliveryAugust 7 - Cancer Drug Discovery: A Synthetic Lethality Approach Using Integrated PlatformsAugust 12 - Radiotracers and ADC Targeting: Scientific Insights for In Vivo Validation and Clinical TransitionAugust 13 - AI in Drug Discovery & Development: Hype, Reality and What Comes NextAugust 21 - Dose Escalation: Optimizing Cohort Management in Early-Phase DevelopmentAugust 26 - AI in Bioprocessing Today — Accelerate. Predict. Deliver. HEALTHCAREAugust 20 - Beyond Diagnosis: The Real-World Impact of AVISE Testing on Lupus, Rheumatoid Arthritis, and Autoimmune Disease Care LABORATORY TECHNOLOGYAugust 6 - Precision Matters: The Critical Role of Accurate Liquid Handling in the Lab MEDICAL DEVICEAugust 25 - Transforming Medical Imaging with AI: Open Tools, Faster Insights PATIENT RECRUITMENT & RETENTIONAugust 20 - Transforming Patient Recruitment: AI and Digital Strategies to Engage the Unreachable 95%August 27 - Enhancing Patient Recruitment in Clinical Research: A Personalized and Engaged Journey PHARMA MANUFACTURING & SUPPLY CHAINAugust 14 - Biofermentation Success Through pH and DO Management PRECLINICALAugust 26 - Advanced In Vivo Efficacy Models for Preclinical Success ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit Contact:Ayesha RashidXtalks ( Tel: +1 (416) 977-6555 x371Email: arashid@ View original content to download multimedia: SOURCE Xtalks Inicia sesión para acceder a tu cartera de valores
Politico
3 hours ago
- Politico
Senate appropriators defend the NIH
WASHINGTON WATCH Senate appropriators came out hard in support of the National Institutes of Health on Thursday, giving the agency a $400 million funding boost for the 2026 fiscal year. How so: The Senate Appropriations Committee upped the agency's budget to $48.7 billion in the 2026 funding bill that cleared the panel with a 26-3 vote Thursday. If the bill becomes law, it would increase cancer research by $150 million; Alzheimer's research by $100 million and amyotrophic lateral sclerosis, or ALS, research by $25 million. The NIH's National Institute of Allergy and Infectious Diseases and the Office of Research on Women's Health would each get a $30 million boost. Research on maternal mortality, diabetes and rare diseases would also see an increase, among others. Why it matters: The funding boost is a rebuke from both Republicans and Democrats to the Trump administration's demand to decrease the NIH funding in the next fiscal year by as much as 40 percent, or $18 billion. Senate Appropriations Chair Susan Collins (R-Maine) said the legislation 'prioritizes funding to help make Americans healthier and supports life-saving medical research.' Sen. Patty Murray (D-Wash.), the top Democrat on the panel, said the budget increase was a message to 'the scientists wondering if there will even be an NIH by the end of this administration. This committee's resounding message is: 'Yes, Congress has your back.'' Murray urged scientists to continue their research in the U.S. despite the efforts of other countries to lure them away. The appropriators also adopted an amendment Thursday that would limit the Trump administration's control over NIH research funding. An amendment in the bill's manager's package limits the administration's plan to shift funding for most NIH grants from a multiyear schedule to an upfront single-year payment. The amendment states that no funds appropriated in the fiscal 2026 spending bill can be used to increase the proportion of grants fully funded in the first year of the award, compared with fiscal 2024. The NIH can only increase that proportion of forward-funded grants if the agency ensures it isn't cutting grants to do so. What's next: The bill is cleared for floor action. But congressional leaders haven't started bipartisan negotiations toward overall government funding totals, increasing the odds that lawmakers will again resort to a stopgap funding patch before the next fiscal year starts on Oct. 1. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Peacock feathers have reflective structures that can amplify light into a laser beam, Science reports. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. MORNING MONEY: CAPITAL RISK — POLITICO's flagship financial newsletter has a new Friday edition built for the economic era we're living in: one shaped by political volatility, disruption and a wave of policy decisions with sector-wide consequences. Each week, Morning Money: Capital Risk brings sharp reporting and analysis on how political risk is moving markets and how investors are adapting. Want to know how health care regulation, tariffs, or court rulings could ripple through the economy? Start here. WORLD VIEW A draft United Nations plan to make the world healthier no longer includes several targets cracking down on sugary drinks, trans fats and tobacco to prevent and control noncommunicable diseases globally. Struck down: A target of 80 percent of countries taxing sugary drinks at levels recommended by the World Health Organization by 2030, POLITICO's Rory O'Neill reports. That goal was a pillar of the initial draft, which will take the form of a nonbinding political declaration world leaders are expected to endorse at a Sept. 25 meeting in New York, on the margins of the U.N. General Assembly. The latest version has also dropped commitments to eliminate trans fats and aims instead to reduce them to the 'lowest level possible.' It also requires front-of-pack labels with nutritional information. A requirement for health warnings on tobacco packaging to be graphic and accompanied by elements that make it unattractive to consumers is also gone. The new draft has softer language on tobacco advertising, requiring countries to restrict it instead of eliminate it. 'Make no mistake, the Declaration in its current form is a backslide,' said Alison Cox, director of policy and advocacy at the NCD Alliance, in a statement. The alliance is a Switzerland-based civil society group working to promote chronic disease prevention. Why it matters: World leaders aim to reduce premature mortality from noncommunicable diseases such as heart disease, cancer and diabetes by 2030 through prevention and treatment and to improve mental health and well-being globally. Noncommunicable diseases killed 18 million people under age 70 in 2021, according to the WHO. Most deaths were in low- and middle-income countries. The aims align with the U.S. Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda, but it's unclear how much the U.S. is involved in drafting the final text. HHS did not respond to a request for comment. What's next: Negotiators are meeting this week in New York to discuss the text.
Yahoo
4 hours ago
- Yahoo
OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025
BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH executive team will be presenting. Event Details Date: Wednesday, August 6, 2025Time: 8:00 a.m. ET / 2:00 p.m. CEST / 9:00 p.m. KSTLocation: Virtual (livestream access)Registration: Opens Monday, August 4 at Available after the event on the OSR Holdings Investor Relations website. Agenda Highlights Corporate overview and strategic vision Subsidiary and R&D pipeline updates: Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies Darnatein: DRT101 – a potent DMOAD candidate Woori IO acquisition: The opportunity for noninvasive CGM Equity Line of Credit (ELOC) financing strategy Blockchain & Tokenization strategy Live Q&A with management "This event is a timely opportunity to engage with our shareholders and the broader investment community as we move into a transformative stage in OSR's growth," said Peter Hwang, CEO of OSRH. "We look forward to showcasing the strength of our platform, the progress we've made, and the catalysts ahead. We are committed to transparency, disciplined execution, and delivering meaningful value to all stakeholders in the coming months."Featured Speakers: Mr. Peter Hwang – Chief Executive Officer Dr. Constance Höfer – Chief Scientific Officer Mr. Tim Smith – Global Investor Relations About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit View original content to download multimedia: SOURCE OSR Holdings Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
